Abstract Background Angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARB) have been shown to have a significant cardioprotective effect in high-risk patients after myocardial infarction (MI). However, there are few data on the effects of these drugs on left-ventricular (LV) remodeling after MI in Japanese patients.
Introduction

Large-scale randomized trials have been conducted to compare the effects of angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-
Is) in suppressing cardiac events in myocardial infarction (MI) patients with compromised left ventricular (LV) function; the results of these studies suggest that the cardioprotective effects of ARBs and ACE-Is are comparable
. (3, 4) . Both (5) (Fig. 1) .
Progression of LV remodeling after MI is an important prognostic factor, and it has been shown in many clinical studies and animal experiments that both ACE-Is and ARBs suppress the progression of LV remodeling through suppression of the activity of the renin-angiotensin (RA) system
Methods
Study subjects and protocol
The subjects of this study were 116 patients with a first anterior-wall MI who were transported to the Critical Care Center of our hospital and received fibrinolysis and subsequent transluminal (FAST) therapy
Measurements of left ventricular volume and function
As indicators of LV remodeling, the left ventricular ejection fraction (LVEF) and left ventricular end-diastolic volume index (LVEDVI) were calculated from left ventriculograms (LVG) obtained in the acute phase (baseline) and at
In (Fig. 2) . T a b l e 1 . P a t i e n t Ch a r a c t e r i s t i c (100) 24 (48) 12 (24) 28 (55) 17 (52) 50 (100) 14(27) 11 (21) 34 (67) 8 (15) 8 (15) 24 (48) (100) 26 (52) 11 (21) 28 (55) 19 (58) 50 (100) 15 (30) 12 (24) 34 (73) 9 (18) 9(18) 26 (52) (100) 100 (100) 23 (23) 54 (54) 55 (55) 100 (100) 29 (29) 23 (23) 70 (70) 17 (17) 17 (17) 50 (50) Regarding the optimal timing of use of ACE-Is, the results of large scale trials (8) (9) (10) F i g u r e 1 . Co r r e l a t i o n b e t we e n t h e b a s e l i n e E F a n d t h e c h a n g e i n E F . F i g u r e 2 . Co r r e l a t i o n b e t we e n b a s e l i n e L VE DVI a n d t h e c h a n g e i n L VE DVI . 
the entire population, the baseline LVEDVI was negatively correlated with the percent change of this parameter observed at 6 months after enrolment in the study (R=-0.677, p<0.0001). A negative correlation between the baseline LVEDVI and the percent change of this parameter at 6 months was also observed in both groups
Thus, in both the enalapril and losartan groups, the percent improvement in LV remodeling after 6 months of treatment, as assessed by the two parameters mentioned above, was higher in the patients with a poorer baseline LV function, and less marked in those with relatively well-preserved LV function (less extensive and/or severe infarction) at baseline. These results suggest that high-risk patients with more extensive infarction are more likely to accrue the beneficial effects of the two classes of drugs examined.
Discussion
The present study had important clinical findings. There was no significant difference in improvement of LV remodeling between the enalapril group and the losartan group, that is, both drugs suppressed LV remodeling to an equivalent degree. It is noteworthy, however, that the effect of both enalapril and losartan in suppressing LV remodeling was greater in patients with more extensive infarction and lower baseline LV function levels. To date, two large-scale randomized clinical studies have been carried out to compare the usefulness of ACE-Is and ARBs for secondary prevention of MI: OPTIMAAL (1) and VALIANT (2). Neither of these revealed any statistically significant difference in the incidence of death from heart failure between patients treated with ACE-Is and those
